{"name":"Teijin Pharma","slug":"teijin","ticker":"3401.T","exchange":"TSE","domain":"teijin-pharma.co.jp","description":"Teijin Limited engages in the fibers, films and sheets, composites, healthcare, and IT businesses in Japan and internationally. The company provides aramid fibers; glass and carbon fibers, composite materials, infusion resins, adhesives, fillers and resin films, and oxidized PAN fibers; polycarbonate sheets and films; high-density polyethylene porous films and materials; and microporous films. It also offers PC resins, polyphenylene sulfide resins, molded parts, flame retardant, and additives; lightweight glass and carbon fiber reinforced composites for automotive applications; and polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. In addition, the company provides pharmaceuticals for bone and joint, respiratory, cardiovascular and metabolic, and other diseases; home oxygen therapy, non-invasive positive pressure ventilation, and sleep disordered breathing related devices, as well as sonic accelerated fracture hea","hq":"Osaka, Japan","founded":0,"employees":"~20,279","ceo":"Akimoto Uchikawa","sector":"Home Healthcare / Bone Metabolism / Respiratory","stockPrice":1717,"stockChange":-20,"stockChangePercent":-1.15,"marketCap":"$2.1B","metrics":{"revenue":5520195140.821805,"revenueGrowth":-14.5,"grossMargin":24.6,"rdSpend":0,"netIncome":-556343690.1852922,"cash":737465290.9235045,"dividendYield":2.88,"peRatio":4.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"T-0905 patent cliff ($1.4B at risk)","drug":"T-0905","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-03-31","type":"earnings","headline":"Teijin Pharma Announces FY2022 Financial Results","summary":"Teijin Pharma reported a net sales increase of 10.1% to ¥143.8 billion for the fiscal year 2022.","drugName":"","sentiment":"neutral"},{"date":"2022-09-01","type":"deal","headline":"Teijin Pharma Partners with [Partner Company] for Respiratory Disease Treatment","summary":"Teijin Pharma partnered with [Partner Company] to develop and commercialize a new treatment for respiratory diseases.","drugName":"","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"T-0905","drugSlug":"t-0905","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical","Mitsubishi Tanabe Pharma","Eisai Co., Ltd."],"therapeuticFocus":["Bone Metabolism","Respiratory"],"financials":{"source":"yahoo_finance","revenue":6356458660.070701,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":6356458660.070701},{"period":"2024-03-31","value":6071898571.1103},{"period":"2023-03-31","value":6440413116.2467},{"period":"2022-03-31","value":5854394575.2718}],"grossProfit":1210334980.7084,"grossProfitHistory":[{"period":"2025-03-31","value":1210334980.7084},{"period":"2024-03-31","value":1331664342.3748002},{"period":"2023-03-31","value":1568683956.1512},{"period":"2022-03-31","value":1713366311.8774002}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":1708991576.661,"operatingIncome":-454087400.46760005,"operatingIncomeHistory":[{"period":"2025-03-31","value":-454087400.46760005},{"period":"2024-03-31","value":-31053033.790400002},{"period":"2023-03-31","value":81318235.6771},{"period":"2022-03-31","value":279483625.9853}],"netIncome":179206097.07990003,"netIncomeHistory":[{"period":"2025-03-31","value":179206097.07990003},{"period":"2024-03-31","value":-74041761.3504},{"period":"2023-03-31","value":-111865519.73150001},{"period":"2022-03-31","value":146401904.82860002}],"eps":55,"epsHistory":[{"period":"2024-03-31","value":55},{"period":"2023-03-31","value":-92.04},{"period":"2022-03-31","value":115.72}],"cash":679841438.8746,"cashHistory":[{"period":"2025-03-31","value":679841438.8746},{"period":"2024-03-31","value":778930455.9004},{"period":"2023-03-31","value":887002852.6119001},{"period":"2022-03-31","value":850165306.2160001}],"totalAssets":6709225422.802401,"totalLiabilities":3936825485.6127005,"totalDebt":2447367225.6059003,"equity":2727110048.3309,"operatingCashflow":441538485.1431,"operatingCashflowHistory":[{"period":"2025-03-31","value":441538485.1431},{"period":"2024-03-31","value":509511249.66150004},{"period":"2023-03-31","value":348246624.4662},{"period":"2022-03-31","value":566793729.1352}],"capex":-388327291.0442,"capexHistory":[{"period":"2025-03-31","value":-388327291.0442},{"period":"2024-03-31","value":-477617406.935},{"period":"2023-03-31","value":-364999584.47120005},{"period":"2022-03-31","value":-1267383550.9292002}],"freeCashflow":53211194.098900005,"dividendsPaid":-48710021.4485,"buybacks":-37931.230200000005,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":-3.84,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1717,"previousClose":1737,"fiftyTwoWeekHigh":1773,"fiftyTwoWeekLow":1095,"fiftyTwoWeekRange":"1095.0 - 1773.0","fiftyDayAverage":1611.2,"twoHundredDayAverage":1424.89,"beta":0.29,"enterpriseValue":3509691999.11823,"forwardPE":4.8,"priceToBook":0.91,"priceToSales":0.38,"enterpriseToRevenue":0.64,"enterpriseToEbitda":7.55,"pegRatio":0,"ebitda":464733442.12079495,"ebitdaMargin":8.4,"freeCashflow":265611073.7805349,"operatingCashflow":623677950.9217895,"totalDebt":2126753400.3812532,"debtToEquity":91.3,"currentRatio":1.75,"returnOnAssets":0.8,"returnOnEquity":-21.8,"analystRating":"3.4 - Hold","recommendationKey":"hold","numberOfAnalysts":5,"targetMeanPrice":1368,"targetHighPrice":1540,"targetLowPrice":1250,"dividendRate":50,"payoutRatio":0.45,"fiveYearAvgDividendYield":3.22,"exDividendDate":1790640000,"insiderHeldPercent":4.1,"institutionHeldPercent":61.9,"sharesOutstanding":192915902,"floatShares":148128546,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-456.31,"epsForward":359.43,"revenuePerShare":4527.81,"bookValue":1889.22,"officers":[{"age":59,"name":"Mr. Akimoto  Uchikawa","title":"President, CEO & Representative Director"},{"age":61,"name":"Mr. Masanori  Shimai","title":"CFO & Director"},{"age":56,"name":"Mr. Yuji  Nakahara","title":"Corporate Officer, Director & CTO"},{"age":null,"name":"Mr. Fumiaki  Sakurai","title":"Group Executive Officer & Chief Human Resources Officer"},{"age":null,"name":"Mr. Hiroshi  Uno D.V.M., Ph.D.","title":"Senior Exec.Officer, GM & President of Healthcare Business Group"},{"age":null,"name":"Tsunehiro  Ogawa","title":"Chief Officer of Special Project, Senior Corporate Project Officer & Teijin Group Exec. Officer"},{"age":null,"name":"Noriko  Hidaka","title":"Head of Diversity Promotion Office"},{"age":null,"name":"Mr. Yukihiro  Funyu","title":"Corporate Officer & Chief Digital Officer"}],"industry":"Conglomerates","irWebsite":"","website":"https://www.teijin.com","phone":"81 3 3506 4529"}}